BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 11111451)

  • 1. Mechanism of action of 5-HT3 receptor antagonists: clinical overview and nursing implications.
    Bremerkamp M
    Clin J Oncol Nurs; 2000; 4(5):201-7. PubMed ID: 11111451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA
    Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
    de Wit R; Aapro M; Blower PR
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
    Aapro M; Blower P
    Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting.
    Goodman M
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):20-32. PubMed ID: 9282378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiemetic drugs.
    Cranwell-Bruce L
    Medsurg Nurs; 2009; 18(5):309-13; quiz 314. PubMed ID: 19927970
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of oral 5-HT3 receptor antagonists for emetogenic chemotherapy.
    Anastasia PJ
    Oncol Nurs Forum; 2000 Apr; 27(3):483-93. PubMed ID: 10785902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
    Mahesh R; Perumal RV; Pandi PV
    Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nausea and vomiting in oncologic therapy. Guidelines for use of setrone].
    Nemec K
    Pharm Unserer Zeit; 2007; 36(5):362-7. PubMed ID: 17722163
    [No Abstract]   [Full Text] [Related]  

  • 11. [An outline of 5-HT3 receptor antagonists (2)--In clinical applications].
    Tsukagoshi S; Ohta J; Taguchi T
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2276-81. PubMed ID: 8259839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacology and clinical experiences with serotonin (5-HT3) receptor antagonists].
    Scholz J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Oct; 32(10):626-8. PubMed ID: 9445561
    [No Abstract]   [Full Text] [Related]  

  • 13. 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment.
    Aapro M
    Oncology; 2005; 69(2):97-109. PubMed ID: 16131816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
    Trigg ME; Higa GM
    J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrum of use and tolerability of 5-HT3 receptor antagonists.
    Haus U; Späth M; Färber L
    Scand J Rheumatol Suppl; 2004; 119():12-8. PubMed ID: 15515406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of ondansetron for chemotherapy-induced nausea and emesis.
    San Angel F
    J Intraven Nurs; 1993; 16(2):84-9. PubMed ID: 8478782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing chemotherapy-induced nausea and vomiting.
    Adams L
    Prof Nurse; 1993 Nov; 9(2):91-4. PubMed ID: 8234387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical practice guidelines on antiemetics in oncology.
    Aranda Aguilar E; Constenla Figueiras M; Cortes-Funes H; Diaz-Rubio García E; Gascon Vilaplana P; Guillém V; Martin-Algarra S
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-emetic therapy in cancer chemotherapy: current status.
    Herrstedt J; Dombernowsky P
    Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.